Pharmacoéconomie : accès libre

A Critical Evaluation of Reporting Practices by the Drug Control Authority

Abstract

Louisa Alcott

The regulation and oversight of pharmaceuticals play a pivotal role in ensuring public health and safety. One of the key players in this arena is the Drug Control Authority (DCA), a governmental body responsible for approving, monitoring, and regulating drugs within a country. The transparency and accuracy of reporting practices by the DCA are crucial in maintaining public trust, safeguarding patient well-being, and upholding the integrity of the pharmaceutical industry. This critical evaluation aims to assess the reporting practices of the DCA, focusing on its implications for public health, regulatory effectiveness, and the overall accountability of the authority. Reporting practices by the DCA involve a spectrum of activities, ranging from initial drug approvals to post-marketing surveillance and adverse event reporting. These practices are vital as they facilitate informed decision-making by healthcare professionals, patients, and regulatory bodies. Transparent and accurate reporting of data and outcomes can prevent the circulation of unsafe or ineffective drugs in the market, minimizing potential harm to patients.